BFM
FULC icon

Boothbay Fund Management’s Fulcrum Therapeutics FULC Stock Holding History

Boothbay Fund Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-190,900
Closed -$1.31M – 1968
2025
Q2 		$1.31M Buy
+190,900
New +$1.02M 0.03% 604
2024
Q4 		– Sell
-129,100
Closed -$461K – 1646
2024
Q3 		$461K Buy
+129,100
New +$958K 0.01% 1017
2022
Q3 		– Sell
-24,100
Closed -$118K – 2357
2022
Q2 		$118K Buy
+24,100
New +$236K ﹤0.01% 1940

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Boothbay Fund Management's FULC Position: Q1 2026 in Review

Boothbay Fund Management reduced its Fulcrum Therapeutics (FULC) stake by 41% in Q1 2026, selling an estimated $1.98M and leaving 303,988 shares worth $2.33M. The position accounts for 0.03% of the portfolio, ranked #555.

Boothbay Fund Management first reported a position in FULC in Q4 2020 and has held it in 11 quarters since. The position peaked at $6.24M in Q3 2025. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Boothbay Fund Management held 303,988 shares of Fulcrum Therapeutics worth $2.33M as of Q1 2026.
  • Boothbay Fund Management sold 213,538 Fulcrum Therapeutics shares in Q1 2026, an estimated $1.98M.
  • Fulcrum Therapeutics made up 0.03% of Boothbay Fund Management's portfolio in Q1 2026, its #555 holding.
  • Boothbay Fund Management first reported a position in Fulcrum Therapeutics in Q4 2020 and has held it in 11 quarters since.
  • Boothbay Fund Management's Fulcrum Therapeutics position peaked at $6.24M in Q3 2025.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.